Table S1 from Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors

Table S1 shows dosing schedule and drug-related treatment-emergent adverse events occurring in at least 10% of patients in this study.